Psychopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: April 23, 2025
Language: Английский
PLoS ONE, Journal Year: 2023, Volume and Issue: 18(10), P. e0293349 - e0293349
Published: Oct. 24, 2023
Long-term adverse experiences following psychedelic use can persist for weeks, months, or even years, and are relatively unexplored in research. Our convergent mixed-method study gained quantitative qualitative data from 608 participants who reported extended difficulties experiences. Data was gathered on the context of use, nature duration challenges they experienced (including a written description these), plus range possible risk factors perceived causes. The most common forms difficulty were feelings anxiety fear, existential struggle, social disconnection, depersonalization derealization. For approximately one-third participants, problems persisted over year, sixth, endured more than three years. It found that shorter predicted by knowledge dose, drug type lower levels during psychoactive experience, while narrower taking guided setting. Implications harm reduction discussed.
Language: Английский
Citations
70
Med, Journal Year: 2024, Volume and Issue: 5(3), P. 190 - 200.e5
Published: Feb. 14, 2024
Language: Английский
Citations
37
Brain Sciences, Journal Year: 2025, Volume and Issue: 15(2), P. 117 - 117
Published: Jan. 25, 2025
Background: Psychedelics are increasingly recognized as a promising and innovative treatment strategy for several mental disorders. However, there is still lively controversy in the medical community regards rationale of their employment, specifically indications potential dangers. Methods: A comprehensive literature search on “MEDLINE/PubMed” “Web Science” was performed from inception to 26 June 2024, cross-checking obtained references. We included all studies, i.e., both clinical preclinical, that supplied original data. Results: initially total 1083 entries, 813 MEDLINE/PubMed 270 Web Science. After duplicate elimination, 903 underwent systematic selection. Primary abstract screening yielded 572 candidates eligibility assessment excluded 331 entries formal grounds. Eligibility led exclusion 501 titles. Finally, 70 articles were this review. Discussion: Preclinical evidence genetic expression, histology behavioral studies soundly consistent with psychedelics possessing neuroplasticity-inducing properties. Despite methodological difficulties, seems be inferentially agreement preclinical findings. it unclear whether “neuroplastic boost” induced by classic might dissociable psychodysleptic effects, thereby reducing psychopathological hazards implied these compounds. Moreover, fact so-called “relaxation priors” should unconditionally beneficial appears debatable, further research clarify possible contraindications psychedelic psychoplastogens within precision medicine perspective.
Language: Английский
Citations
7
Communications Psychology, Journal Year: 2025, Volume and Issue: 3(1)
Published: April 13, 2025
Altered states of consciousness (ASCs), induced e.g. during psychedelic-assisted therapy, show potential to treat prevalent mental health disorders like depression and posttraumatic stress disorder. However, access such treatments is restricted by legal, medical, financial barriers. Circular breathwork may present a non-pharmacological hence more accessible alternative engage similar therapeutic processes. Scientific studies are only just emerging its physiological psychological mechanisms largely unknown. Here, we track experiential dynamics throughout session, comparing two forms breathwork: Holotropic Conscious-Connected breathwork. We that reduction in end-tidal CO2 pressure due deliberate hyperventilation significantly correlated ASC onset (r = -0.46; p < 0.001). Based on standard questionnaires (MEQ-30 11-DASC), the ASCs evoked resembled those produced psychedelics across several domains as ego dissolution, their depth predicted follow-on effects, including improved well-being reduced depressive symptoms. Further analysis showed different approaches highly outcomes. Our findings identify boundary conditions for arise context, shedding light functional well psychotherapeutic tool.
Language: Английский
Citations
2
Psychedelic Medicine, Journal Year: 2023, Volume and Issue: 1(4), P. 218 - 229
Published: Oct. 18, 2023
Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role psychosocial interventions (PIs) clinical trials psychedelic treatment due part to deficiencies reporting practices found existing literature. These PI include non-drug support or provided by psychotherapists facilitators during all phases treatment, sometimes called "psychological support," "monitoring," "psychedelic-assisted therapy," psychotherapy." A brief review research, historical studies, safety considerations, and participant perspectives suggests that substantive critical impact outcomes. This systematic examines published trial results. The employs search PubMed/Medline PSYCinfo databases identify relevant articles. It includes quantitative studies treating patients with psychiatric indications using classic psychedelics (psilocybin, LSD, DMT, ayahuasca) empathogenic drugs (MDMA) since 2000. analytic approach follows modified version assessment items based CONSORT extension statement TIDieR checklist. Thirty-three met criteria. reveals many reports did not report basic aspects intervention: 33% number sessions, 45% duration 42% provider credentials, 52% whether their intervention used manual, 64% reference manual was available readers, 82% they assessed fidelity. comparison non-psychedelic shows underreport key related PI. study highlights problems underreporting importance improving regarding enhance research standardization improve Recommendations for are provided.
Language: Английский
Citations
23
Journal of Psychopharmacology, Journal Year: 2024, Volume and Issue: 38(8), P. 690 - 700
Published: July 31, 2024
Objective: Despite considerable research examining the efficacy of psychedelic-assisted therapies (PATs) for treating psychiatric disorders, assessment adverse events (AEs) in PAT has lagged. Current AE reporting standards trials are poorly calibrated to features that distinguish it from other treatments, leaving many potential AEs unassessed. Methods: A multidisciplinary working group experts involved pooled formally and informally documented observed through experience published literature. This information was integrated with (a) current practices pharmacotherapy psychotherapy (b) findings documenting post-acute dosing impacts psychedelics on subjective states, meaning, psychosocial health variables, produce a set constructs important evaluate as well recommended methods time frames their monitoring. Correspondence between identified examined, including extent coverage by 25 existing measures used relevant research. Results: Fifty-four terms warranting systematized were identified, defined, categorized. Existing demonstrated substantial gaps constructs. Recommendations developed how assess (including patient, clinician, informant reports), when over preparation, session, integration, follow-up. Application this framework is preliminary protocol (available supplement). Conclusions: addresses need capture PAT, accounting its components, worldviews spirituality.
Language: Английский
Citations
14
Psychoactives, Journal Year: 2024, Volume and Issue: 3(2), P. 215 - 234
Published: April 16, 2024
Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporting has shifted overstatement risks psychedelics to overly positive hype. As empirical evidence is more equivocal than frequently portrayed, conclusions about effectiveness should be considered preliminary. Poor science communication psychedelics’ therapeutic potential may lead participants or patients feel misled and policy decisions misinformed. An evidence-informed characterization their benefits needed. Objectives: This article assesses state for treating depression effect sizes on outcomes, risk bias, prevalence adverse effects. We review discuss how following treatments have shown decreasing over time: (1) cognitive behavioral therapy, (2) mindfulness interventions, (3) selective serotonin reuptake inhibitors, (4) ketamine. speculate that similar trend occur treatments. Results conclusions: It likely larger better-controlled trials will demonstrate smaller are comparable other conventional emerging mood disorders. Clear critical setting public expectations policy. With this evidence-based assessment, we aim cut through misinformation benefits, risks, future prospects
Language: Английский
Citations
12
Journal of Psychoactive Drugs, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 10
Published: Feb. 10, 2024
Interest in psychedelics and their possible therapeutic potential has been growing. Metaphysical belief theory asserts that these benefits stem from the adoption of comforting supernatural beliefs following a mystical experience. By contrast, predictive self-binding suggests beneficial outcomes are primarily driven by psychological insights. The present study tests competing models psychedelic benefits. We conducted quantitative content analysis on unsolicited self-reports users available Erowid.org, to examine relations between insight, ego dissolution, intent, altered metaphysical belief, enduring health outcomes. randomly selected, coded, analyzed two hundred forty experience reports website. Path using structural equation modeling showed not beliefs, uniquely predicted Moreover, outcomes' positive relation dissolution intent was fully mediated insight. These findings support model over model.
Language: Английский
Citations
9
JAMA Psychiatry, Journal Year: 2025, Volume and Issue: 82(3), P. 311 - 311
Published: Jan. 8, 2025
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This due to a combination promising clinical trial results, positive media coverage, lack novel pharmacologic treatments for psychiatric disorders recent decades. However, field faces key methodological challenge: masking participants treatment conditions trials has been largely unsuccessful. When can tell whether they received active drug or placebo, their responses assessments, questionnaires, even functional imaging biological data be influenced by preconceptions about effects. Positive expectancies combined with ineffective may skew outcomes inflate effect sizes. complicates efforts determine safety efficacy Here, we explore method help address this problem: modifying informed consent obscure information study design. We reviewed all contemporary (2000-2024) methylenedioxymethamphetamine (MDMA) therapy corresponded investigators compile on use modifications these studies. Modifying details design implemented several offer way strengthen masking. approach poses significant ethical risks. examine examples used literature, discuss current regulatory landscape, suggest strategies mitigate risks associated modified consent. Incorporating future improve interpretability impact, but not explicitly tested. Modifications appropriate cases, should minimized implementing guardrails.
Language: Английский
Citations
1
Neuroscience & Biobehavioral Reviews, Journal Year: 2025, Volume and Issue: 172, P. 106086 - 106086
Published: March 1, 2025
Language: Английский
Citations
1